Furthermore, OR of prokineticin-2 to MS was 1.240 (95 % confidence interval: 1.084–1.419, P = 0.002) with adjustment for age, men, and BMI in model 2, or 1.307 (95 % confidence interval: 1.127–1.515, P < 0.001) with adjustment for age, men, BMI, hypertension, history of lipid disorders, type 2 diabetes, lipid-lowering treatment, anti-hypertension therapy, and hypoglycemic treatment in model 3 respectively. Here, PROK2 is linked to myeloid sarcoma.